Health & Education · Valencia, Barcelona, and Madrid

DeLLphi-305 trial cuts small cell lung cancer death risk 58% as Spain marks lung cancer day

A phase III trial published in The New England Journal of Medicine found that a two-drug combination lowered the risk of death by 58% in advanced small cell lung cancer. Spain's World Lung Cancer Day, 17 November, also brought donations, a new screening pathway and fresh incidence estimates.

AI text based on reports by ABC TU DIARIO EN ESPAÑOL, LaVanguardia, El Periódico and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Valencia, Barcelona, Madrid, Nice · Spain, France

A trial result for advanced small cell lung cancer

Hospital La Fe in Valencia took part in DeLLphi-305, an international phase III trial published in The New England Journal of Medicine. The study tested a combination of two drugs in patients with advanced small cell lung cancer whose disease had not progressed after initial standard treatment with chemotherapy and immunotherapy. The combination lowered the risk of death by 58% and the risk of progression or death by 66%, and both drugs were found to extend overall survival. The trial ran at 175 centres in 29 countries and enrolled 563 patients, and La Fe is described as the Spanish hospital with the most experience, having enrolled the largest number of participants. Small cell lung cancer makes up roughly 10% to 15% of all lung tumours and has had limited treatment options until now.

Oscar Juan-Vidal, the La Fe oncologist who took part in the study, said:

“They represent one of the most important advances recorded in recent decades in advanced small cell lung cancer, a particularly aggressive disease with limited treatment options.”

Oscar Juan-Vidal
Risk reduction with two-drug combination in DeLLphi-305 trial%
Risk of death
58 %
Risk of progression or death
66 %

Data from the article text

Donations and fundraising on the day

Sabadell Seguros gave 40,000 euros to the Asociación Contra el Cáncer in Barcelona for a precision medicine project on small cell lung cancer led by oncologist Pedro Rocha. The research aims to identify biomarkers that predict which treatments will work best for each patient and to understand how resistance develops. Sabadell has supported the association since 2018 and has directed around 600,000 euros to initiatives with several partner organisations in recent years.

Metropolitan, a sports club chain, announced on Tuesday, 17 November, that it had raised 55,175 euros for The Ricky Rubio Foundation. The money came from the second edition of Social MET, which mobilised thousands of people in Spain and France. The Saturday MET Live session drew more than 4,000 participants at the same time in cities including Barcelona, Madrid, Bilbao, Sevilla and Nice, and blue wristbands sold for five euros. The funds will support WINNER, a multicentre trial testing a personalised exercise programme before and after surgery for patients with non-small cell lung cancer. Ricky Rubio, the foundation's president, said:

“In The Ricky Rubio Foundation we believe research is fundamental to keep advancing against lung cancer.”

Ricky Rubio, joventut basketball player and president of The Ricky Rubio Foundation

Screening and rapid diagnosis

Hospital Vithas Barcelona has launched a screening and rapid diagnosis programme that keeps the whole pathway in one place. Screening targets people without symptoms who are at high risk, mainly smokers and former smokers with heavy tobacco exposure. A patient can see a pulmonologist, have a low-radiation CT scan and receive an initial radiology assessment at the same centre on the same day. Suspicious lesions move straight to a multidisciplinary committee. Juan Pablo Orozco, head of the pulmonology department, said:

“The aim is to reduce as much as possible the time between the first diagnostic suspicion and clinical decisions, avoiding unnecessary delays at a particularly sensitive moment for the patient.”

Juan Pablo Orozco, head of the pulmonology department at Hospital Vithas Barcelona

Víctor Albarrán Artahona added that the coordination lets the team judge the risk of each lesion quickly, decide whether a biopsy is needed and choose the right treatment if cancer is diagnosed.

Incidence and the case for prevention

According to National Statistics Institute (INE) data, lung cancer is the main cause of cancer death in Spain. The 2026 estimate is 34,908 new cases, of which 23,079 are expected in men and 11,829 in women, and the Spanish Society of Medical Oncology (SEOM) projects about 35,000 new cases. The Valencian Institute of Oncology, which marks 50 years of activity, notes that lung cancer has overtaken breast cancer as the leading cause of cancer death among women in the latest 2024 data. Tobacco is linked to about 85% of cases, and the Institute also cites secondhand smoke, radon, uranium, asbestos and diesel exhaust.

Estimated new lung cancer cases in Spain in 2026, by sexcases
Men
23079 cases
Women
11829 cases

Data from the article text

Pilar Garrido López, head of medical oncology at the Ramón y Cajal hospital in Madrid, said at an El Mundo roundtable that lung cancer needs more visibility, support from the authorities and resources as incidence keeps rising, especially in women. She listed three priorities: ending tobacco use, introducing screening and faster access to diagnostic innovation.

Ask about this text

Sources and context

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar